Clinical Trials · NCT03007732
Pembrolizumab +/- SD-101 in Hormone-Naïve Oligometastatic Prostate Cancer With RT and iADT
- Phase
- Phase 2
- Recruitment status
- Completed
- Sponsor
- David Oh
- Enrollment
- 23
- Start date
- May 2017
- Locations
- 1 site, United States
- Primary endpoint
- Change Rate of Prostate-specific Antigen (PSA) < Nadir + 2 ng/mL From First Day of Treatment to 15 Months (Cohort 2)